Several ADCs targeting CD22 have been developed, including inotuzumab ozogamicin, FDA approved for use in relapsed/refractory B-ALL, and moxetumomab pasudotox-tdfk, approved for use in patients with R/R hairy cell leukemia (HCL) after two prior lines of therapy. This evidence concerns the gene CD22 and hairy cell leukemia.